China National Pharmaceutical Group: SINOPHARM has reported the infringement and unfair competition behavior of Medicinal Materials Co., Ltd. to the public security organs in accordance with the law

On February 12, Jinshi Data reported that recently, China National Pharmaceutical Group Corporation and its affiliated enterprises have repeatedly encountered legal disputes, including incidents of defaulting on payments to construction units and even rural collective enterprises. China National Pharmaceutical Group Corporation also frequently receives complaint letters. The statement from China National Pharmaceutical Group is as follows: Since November 2016, China National Pharmaceutical Group's subsidiary, China Traditional Chinese Medicine Co., Ltd., has held a 25% stake in China National Pharmaceutical Co., Ltd. China National Pharmaceutical Group and China Traditional Chinese Medicine are neither the controlling shareholders nor the actual controllers of China National Pharmaceutical Co., Ltd. Regarding the alleged infringement of China National Pharmaceutical Group's trademark rights and acts of unfair competition by China National Pharmaceutical Co., Ltd., China National Pharmaceutical Group and China Traditional Chinese Medicine have filed lawsuits in accordance with the law; concerning the illegal acts of fabricating shareholder meetings, forging shareholder meeting resolutions, forging signatures of China Traditional Chinese Medicine's directors, and falsifying company articles of association, China Traditional Chinese Medicine has filed lawsuits in accordance with the law and has received support from the court; regarding the criminal acts of China National Pharmaceutical Co., Ltd. in forging seals, a report has been filed with the public security authorities in accordance with the law